Is Alumexx N.V. (AMS:ALX) A High Quality Stock To Own?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...
Jefferies上调ALX Oncology评级至买入，目标价提升至3美元
周四，Jefferies分析师Michael Yee对ALX Oncology股票提供了积极展望，将该股评级从持有上调至买入，并将目标价从2.00美元上调至3.00美元。Yee的乐观立场基于对愿意承担投机风险的投资者而言较为有利的风险收益比。目前该股交易价格为1.04美元，过去一年股价下跌了93%。根据 InvestingPro ...
Stifel下调ALX Oncology目标价至1.50美元，维持持有评级
周五，Stifel分析师调整了对ALX Oncology（NASDAQ:ALXO）的展望，将目标价从此前的3.00美元下调至1.50美元，同时维持对该股的持有评级。目前该公司股价为1.24美元，市值为6540万美元，过去一年股价下跌超过90%。该公司分析师Bradley Canino解释了这一决定，指出对公司发展战略和监管风险的担忧。根据 InvestingPro 数据，ALX ...
Fierce Biotech11 天
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
Bay Area biotech firm once worth more than $4B lays off 30% of staff
ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...
Atlas Arteria's (ASX:ALX) Solid Earnings May Rest On Weak Foundations
ASX:ALX Earnings and Revenue History March 11th 2025 The Impact Of Unusual Items On Profit. To properly understand Atlas ...
ALX Oncology to Cut 30% of Workforce, Names New CFO
ALX Oncology is cutting about 30% of its workforce and realigning its focus. The clinical-stage biotechnology company named Harish Shantharam as chief financial officer and Alan Sandler as chief ...
ALX Oncology will highlight progress across its clinical pipeline
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...